Thus, our results revealing significant inhibition of Tn, T antigens, and their sialylated forms, enhanced by combined therapy, strongly support the rationality of potential anti-MUC1 application in gastric cancer treatment. This evidence concerns the gene MUC1 and gastric cancer.